TPP-based conjugates: potential targeting ligands

Drug Discov Today. 2024 Apr 17:103983. doi: 10.1016/j.drudis.2024.103983. Online ahead of print.ABSTRACTMitochondria are one of the major sources of energy for, as well as regulators of, cancer cell metabolism. Thus, they are potential targets for the effective treatment and management of cancer. Research has explored triphenylphosphonium (TPP) derivatives as potent cancer-targeting ligands because of their lipophilic nature and mitochondrial affinity. In this review, we summarize the utility of TPP-based conjugates targeting mitochondria in different types of cancer and other diseases, such as neurodegenerative and cardiovascular disorders. Such conjugates offer versatile therapeutic potential by modulating membrane potential, influencing reactive oxygen species (ROS) production, and coupling of molecular modifications (such as ATP metabolism and energy metabolism). Thus, we highlight TPP conjugates as promising mitochondria-targeting agents for use in targeted drug delivery systems.PMID:38641237 | DOI:10.1016/j.drudis.2024.103983
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research